Cells detect forces ranging from tiny touch signals, like the brush of a feather on the skin, to relatively large pressure changes, like those affecting blood vessels. How such mechanical stimuli are detected by mammalian cells is still a matter of debate. It is clear that ion channels, including stretch-activated cation channels (SACs), play an important role. It is unclear, however, whether SACs are gated by directly sensing mechanical forces, such as membrane stretching or pressure, or by indirect signals generated by remote mechanosensors. Direct gating may occur by changes in the surface tension of the plasma membrane (bilayer model) or by force transmission through cytoskeletal elements tethered to the channel (tethered model). Indirect gating may occur when channels receive signals from remote mechanosensors, for example via G proteins or phospholipases (Christensen and Corey, 2007) . The molecular identity of SACs is still unknown. SACs are predicted to be nonselective Ca 2+ -permeable cation channels and may belong to the family of transient receptor potential (TRP) channels, although recent data have cast doubt on this hypothesis (Gottlieb et al., 2008) . New work from Eric Honoré's group (Sharif-Naeini et al., 2009 ) published in this issue reveals the identity not of the SACs per se but of a key regulator. The modulator of SAC activity turns out to be the polycystin TRPP2 (PKD2), a member of the TRP ion channel family. The authors show that in mouse arterial muscle cells, TRPP2 acts neither as a channel nor as a "mechanosensor" but rather regulates the activity of SACs, enabling sensing of the pressure in the lumen of blood vessels. Ironically, then, the functionally well-defined SACs remain unidentified, whereas a protein known to function as a channel in some cells is not a channel but a channel regulator in arterial muscle cells.
TRPP2 is a six-transmembrane domain protein that may form a Ca 2+ -permeable cation channel in association with TRPP1 (polycystin 1 or PKD1). TRPP1 is a large glycoprotein consisting of 11 transmembrane domains, a very long (~3000 amino acids) and complex extracellular domain, and an intracellular C-terminal domain that interacts with the C terminus of TRPP2. Mutations in either protein cause autosomal-dominant polycystic kidney disease (Nilius et al., 2007) . The TRPP1/ TRPP2 polycystin complex serves several functions in most eukaryotic cells. It acts as a mechanosensory channel in the primary cilium, a nonselective cation channel in the plasma membrane, and a Ca 2+ release channel in the endoplasmic reticulum (Köttgen and Walz, 2005) .
Polycystins are also abundantly expressed in the muscle cells (myocytes) of blood vessels, but their function in this system has been unclear. In blood vessel myocytes, increasing intralumenal pressure triggers the opening of SACs, resulting in the activation of voltagedependent Ca 2+ channels and leading to vessel contraction (the so-called myogenic response or "Bayliss effect") (Davis and Hill, 1999) . Using two elegant approaches, Sharif-Naeini et al. (2009) now show that TRPP2 inhibits the activity of endogenous SACs in several cell types. First, in a heterologous expression system, they directly measured pressure-induced single-channel currents through endogenous SACs. They found that expression of TRPP2 does not induce channel activity but instead inhibits SACs, whereas expression of both TRPP1 and TRPP2 reverses this inhibition. TRPP1 likely acts by sequestering TRPP2. Indeed, mutagenesis experiments showed that a truncated TRPP2, lacking the C terminus TRPP1-binding domain, can still inhibit SAC activity. However, TRPP1 is unable to reverse the inhibition of SAC activity by the truncated TRPP2, consistent with the idea that the effect of TRPP1 on TRPP2 depends on an interaction between the two proteins. Thus, it appears that the ratio of TRPP1 to TRPP2 regulates the activity of the elusive SACs. Second, the investigators used the Cre/lox strategy to selectively inactivate the TRPP1 gene in mouse mesenteric arterial smooth muscle cells. Knocking out TRPP1 in these myocytes reduced SAC activity, probably by releasing TRPP2, thereby diminishing the Bayliss response ( Figure  1 ). When the investigators silenced both TRPP1 and TRPP2, however, SAC activity and the myogenic response recovered. These results support the idea that TRPPs regulate SACs. Thus, whereas the SAC stretch responder has yet to show its true colors, we at least now know that the TRP channel is a modulator of SAC activity.
The authors also provide exciting mechanistic data. Here, the tethering model comes into play. Sharif-Naeini et al. find that TRPP2 associates with a cytoskeletal component, the protein filamin A. Filamins crosslink cortical actin into a dynamic three-dimensional structure that is mechanoprotective, i.e., it causes inhibition of SAC activity. TRPP2 may associate with the actin cytoskeleton via filamin A, as knocking down filamin A reduces the inhibition of SAC activity by TRPP2. Furthermore, disruption of the F-actin cytoskeleton, but not the micro- tubule network, also blocks SAC inhibition by TRPP2. The authors propose that the TRPP2/filamin A/actin association might decrease the radius of membrane curvature around SACs. According to the law of Laplace (tension is proportional to the radius of curvature), this would lead to a reduction in the amount of tension acting on SACs, resulting in reduced SAC activity. Disturbing the association between TRPP2 and filamin A, either by increasing the TRPP1/TRPP2 ratio or by disruption of the cytoskeleton, may increase this radius and promote SAC activation. These results are among the first to show an interplay between the bilayer and the cytoskeleton in the regulation of SAC gating, suggesting a combination of both bilayer and tether models for the gating of SACs.
Although these findings are a step forward for SAC channel hunters, the real target, the nonselective SAC, remains elusive. The good news: the new study also provides a very valuable supplement, listing 79 TRPP2-associated proteins including several intriguing transmembrane proteins. The next step, then, should be the identification of the SAC itself. Nevertheless, some important questions remain. Given that TRPP2 also resides in the endoplasmic reticulum and sarcoplasmic reticulum, can TRPP2 in these locations also interact with filamin A to inhibit SACs? What is the role of other TRPP2-interacting partners? Can they substitute for TRPP1 in relieving SAC inhibition? How is the TRPP2-SAC interaction regulated?
The new work by the Honoré group provides the first demonstration of a role for polycystins in sensing the pressure in blood vessels. The findings identify TRPP2 as a potential therapeutic target that could be used in the management of arteriolar myogenic tone. Myogenic tone plays essential roles in the regulation of vascular resistance, blood pressure, and capillary hydrostatic pressure (Hill et al., 2009) . Polycystins are also important for the structural integrity of blood vessels. Indeed, patients carrying TRPP1 or TRPP2 mutations who develop autosomal-dominant polycystic kidney disease also suffer from aneurysms, vessel rupture, and internal bleeding as well as structural defects in the heart such as defective septum formation and mitral valve prolapse (Nilius et al., 2007) . The new results from Sharif-Naeini et al. suggest that these structural defects perhaps are the result of defective pressure sensing. Last, but not least, the new work raises the possibility that pressure sensing is also involved in renal pathogenesis in polycystic kidney disease.
figure 1. Polycystins and Pressure sensing in Blood Vessels
(A) The polycystin TRPP2 (PKD2) is a six-transmembrane domain protein that associates with and inhibits an unidentified stretch-activated cation channel (SAC) in vascular smooth muscle cells. TRPP2 is connected via filamin A to the cortical F-actin cytoskeleton, which also has an inhibitory effect on SAC activity, known as the mechanoprotective cytoskeletal effect. (B) The association between TRPP2 and another polycystin, a large transmembrane domain protein called TRPP1 (PKD1), relieves SAC inhibition. (C) In the myogenic response of blood vessels (also called the Bayliss effect), an increase in intralumenal blood pressure causes vasoconstriction (blue line), which depends on the contraction of smooth muscle cells and requires SAC activity. TRPP2 inhibits SAC activity and dramatically decreases the myogenic response (red line). On the other hand, sequestration of TRPP2 by TRPP1 restores SAC activity and the myogenic response. The dotted red line shows passive vessel dilation level, in response to pressure, in the absence of the myogenic response.
